

Announcement No. 9/2009

To NASDAQ OMX Copenhagen A/S and the press

Copenhagen, 14 May 2009

Exiqon A/S issues new warrants

The supervisory board of Exiqon A/S has today 14 May 2009 resolved to issue 10,000 warrants to an employee in Exiqon A/S. All warrants have been issued in accordance with the authorization granted in article 3c of the articles of association.

The warrants issued entitle the warrant holder to subscribe for in total up to nom. DKK 10,000 shares of DKK 1.00 each in Exiqon A/S, and the supervisory board has at the same time resolved to increase the Exiqon A/S' share capital accordingly.

The exercise price for the issued warrants is DKK 18.02 per warrant which corresponds to the average closing price of the Company's shares in the last five trading days up to and including 13 May 2009, plus 5% per year.

Of the warrants issued one thirty-sixth (1/36) hereof are vested as from the first day of the calendar month following the date of issuance of these warrants. Another one thirty-sixth (1/36) of these warrants are vested as from the first day of each new calendar month until all of these warrants have become vested. Unexercised warrants become null and void after expiry of the first exercise period following 36 months after allocation.

The resolution of the supervisory board has been included in article 3c7 of the company's articles of association.

For more information, please contact:

Lars Kongsbak, President and CEO, tel. + 45 40 90 21 01

Hans Henrik Chrois Christensen, CFO, tel. +45 45 65 09 53 or + 45 40 90 21 31

About Exiqon

Exiqon is a biotech company with activities in three business areas where the company's technologies provide a competitive advantage: sale of diagnostic tests (Exiqon Diagnostics), sale of innovative research products for miRNA research (Exiqon Life Sciences), and in contract research together with pharmaceutical companies (Exiqon Pharma Services). Exiqon is dedicated to personalizing the treatment selection for cancer patients. The aim is to optimize the use of existing medicine and avoid unnecessary and non-effective treatment. By using molecular diagnostic tests that analyse the genetic profile of each patient's tumor, treatment selection can be optimized for individuals. Exiqon is uniquely positioned to develop such new diagnostic tests. Exiqon already markets diagnostic tests that based on fresh tumor tissue enable doctors to test whether their patients are resistant to one or more of the chemotherapies offered to treat these patients and help them select an efficacious treatment. Exiqon's new molecular diagnostic products are based on the LNA™ technology that enables testing on fixed tissue. The first molecular diagnostic product was launched in December 2008. A number of new products will follow in the years ahead. Using the LNA™ technology is what has allowed Exiqon to establish a position for itself as one of the market's leading providers of research products for gene expression analysis. These research products are used by university scientists and in the pharmaceutical industry around the world to make groundbreaking discoveries about the correlation between gene activity and the development various diseases. Exiqon is also collaborating with pharmaceutical companies in their effort to develop new medicines based on biomarkers (Personalized Medicine). Exiqon has more than 200 employees and is listed on the NASDAQ OMX in Copenhagen and categorized as a biotech company (Small Cap+). Exiqon is financed until expected breakeven in 2011.

Disclaimer

Forward-looking statements:

This announcement contains forward-looking statements regarding Exiqon's potential future development and financial performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of Exiqon's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon's operations are characterized by the fact that its actual results may deviate significantly from that described herein as anticipated, believed, estimated or expected.